Low expression of BUB1B contributes to poor survival and metastasis in human colon adenocarcinomas [18] and lung cancer [19], while overexpression of BUB1B is related to progression and recurrence of gastric cancer [20], bladder cancer [21], HCC [22], and many other cancers [23–25]. Here, BUB1B is linked to urinary bladder carcinoma.